8-K: U.S. Physical Therapy Reports Strong Q3 2025 Results

U.S. Physical Therapy, Inc. announced robust third-quarter 2025 results, driven by significant clinic expansion and double-digit growth in its industrial injury prevention services.

Summary

• Adjusted EBITDA, a non-GAAP measure, was $23.9 million for the three months ended September 30, 2025, an increase of 13.2% from $21.1 million in the prior year period.
• Net income attributable to USPH shareholders was $13.1 million for Q3 2025, compared to $6.6 million for Q3 2024.
• Earnings per share was $0.48 for Q3 2025, up from $0.39 in Q3 2024.
• Total revenue from physical therapy operations increased 17.8% to $168.1 million for Q3 2025.
• Total patient visits increased 18.0% to 1,554,207 for Q3 2025, including 30,137 home-care visits.
• Average daily patient visits per clinic, excluding home-care, reached a record-high 32.2 for a third quarter.
• Industrial injury prevention services (IIP) revenue increased 14.6% to $29.0 million for Q3 2025.
• The company added 18 and closed 7 owned and/or managed clinics in Q3 2025, bringing its total count to 779 as of September 30, 2025.
• A quarterly dividend of $0.45 per share was declared, payable on December 12, 2025, to shareholders of record on November 17, 2025.
• Management reaffirmed its full-year 2025 Adjusted EBITDA guidance range of $93.0 million to $97.0 million.

Sentiment

Score: 8

Explanation: The company reported strong Q3 2025 results with significant increases in net income, Adjusted EBITDA, and patient visits, driven by successful clinic expansion and growth in industrial injury prevention services. While some operating costs and interest expenses rose, the overall performance indicates robust operational health and strategic execution. Management's reaffirmation of full-year guidance and positive outlook for 2026 further supports a strong sentiment.

Positives

• Adjusted EBITDA increased by 13.2% to $23.9 million for Q3 2025, primarily driven by clinic additions.
• Net income attributable to USPH shareholders more than doubled to $13.1 million for Q3 2025 from $6.6 million in Q3 2024.
• Earnings per share increased to $0.48 in Q3 2025 from $0.39 in Q3 2024.
• Total revenue from physical therapy operations rose 17.8% to $168.1 million in Q3 2025.
• Physical therapy operations gross profit increased 30.0% to $31.2 million for Q3 2025.
• Total patient visits increased 18.0% to 1,554,207 in Q3 2025.
• Average daily patient visits per clinic reached a record-high 32.2 for a third quarter, up 7.0% from 30.1 in Q3 2024.
• Industrial injury prevention services (IIP) revenue increased 14.6% to $29.0 million for Q3 2025.
• IIP gross profit increased 10.7% to $5.7 million for Q3 2025.
• The company expanded its clinic count to 779 as of September 30, 2025, adding 84 net owned clinics since Q3 2024.
• A net gain of $5.9 million was recognized from the revaluation of contingent consideration in Q3 2025, compared to a net loss of $1.9 million in Q3 2024.
• Operating income increased to $25.3 million for Q3 2025 from $12.8 million for Q3 2024.
• Management reaffirmed its full-year 2025 Adjusted EBITDA guidance range of $93.0 million to $97.0 million.
• A quarterly dividend of $0.45 per share was declared.

Negatives

• Operating Results (non-GAAP) decreased to $10.1 million ($0.66 per share) for Q3 2025 compared to $10.4 million ($0.69 per share) for Q3 2024.
• Net rate per patient visit slightly decreased to $105.54 for Q3 2025 from $105.65 for Q3 2024.
• Adjusted gross profit margin for physical therapy operations decreased to 18.6% in Q3 2025 from 19.2% in Q3 2024.
• Operating costs per visit for physical therapy operations increased to $86.88 in Q3 2025 from $86.00 in Q3 2024.
• IIP gross profit margin decreased to 19.6% for Q3 2025 from 20.3% for Q3 2024.
• Corporate office costs increased to $17.4 million for Q3 2025 from $14.4 million for Q3 2024, partly due to acquisition integration and new system implementation costs.
• Interest expense increased by $0.4 million to $2.4 million for Q3 2025 due to a higher average outstanding balance on the revolving credit facility and a higher effective interest rate (5.7% in Q3 2025 vs 5.4% in Q3 2024).
• Interest income decreased significantly to less than $0.1 million in Q3 2025 from $1.0 million in Q3 2024, as excess cash was deployed for acquisitions.
• A net non-cash expense of $0.7 million was recognized for the revaluation of a put-right liability related to a future IIP business purchase, compared to a net non-cash gain of $0.2 million in Q3 2024.
• Cash and cash equivalents decreased to $31.1 million as of September 30, 2025, from $117.0 million as of September 30, 2024.

Risks

• Changes in Medicare rules and guidelines and reimbursement or failure of clinics to maintain their Medicare certification and/or enrollment status.
• Revenue from Medicare and Medicaid being subject to potential retroactive reduction.
• Changes in reimbursement rates or payment methods from third-party payors, including government agencies, and changes in patient deductibles and co-pays.
• Private third-party payors for services may adopt payment policies that could limit future revenue and profitability.
• Compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply.
• Compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply.
• Competitive, economic or reimbursement conditions in markets which may require reorganization or closure of certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets.
• The impact of future public health crises and epidemics/pandemics.
• Certain acquisition agreements contain put-rights related to a future purchase of significant equity interests in subsidiaries or in a separate company.
• The impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations.
• Debt and financial obligations could adversely affect financial condition, ability to obtain future financing and ability to operate the business.
• Changes as the result of government enacted national healthcare reform.
• The ability to control variable interest entities for which there is no direct ownership.
• Governmental and other third-party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs.
• Contingent consideration provisions in certain acquisition agreements, the value of which may impact future financial results.
• Legal actions, which could subject the company to increased operating costs and uninsured liabilities.
• General economic conditions, including but not limited to inflationary and recessionary periods.
• Actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S or the international financial systems, may result in market-wide liquidity problems.
• Business depends on hiring, training, and retaining qualified employees.
• Availability and cost of qualified physical therapists.
• Competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements.
• Ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses.
• Impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests).
• Maintaining information technology systems with adequate safeguards to protect against cyber-attacks.
• A security breach of information technology systems may subject the company to potential legal action and reputational harm and may result in a violation of HIPAA.
• Maintaining clients for which management, industrial injury prevention related services, and other services are performed, as a breach or termination of those contractual arrangements could cause operating results to be less than expected.
• Maintaining adequate internal controls.
• Maintaining necessary insurance coverage.
• Availability, terms, and use of capital.
• Weather and other seasonal factors.

Future Outlook

Management reaffirmed its full-year 2025 Adjusted EBITDA guidance range of $93.0 million to $97.0 million. The company expects continued clinic expansion and sustained growth in its injury prevention business, with progress on key initiatives anticipated to benefit 2026 growth and performance, along with an expected and overdue Medicare pricing lift. Implementation costs for a new financial and human resources system are expected to continue through the end of 2026.

Management Comments

• Chris Reading, CEO, stated that Q3 2025 was a very solid quarter across the board with record visits per clinic per day, continued clinic expansion with 84 net owned additions since the third quarter of 2024, and sustained double-digit growth in the injury prevention business.
• Chris Reading also noted that the company is making progress on some key initiatives that will benefit 2026 growth and performance, along with an expected and overdue Medicare pricing lift.

Industry Context

The physical therapy and industrial injury prevention sectors are experiencing growth, as evidenced by U.S. Physical Therapy's clinic expansion and increased patient visits. The company's focus on acquisitions and organic growth through satellite clinics aligns with a strategy to capture market share in a fragmented healthcare services landscape. The mention of an "expected and overdue Medicare pricing lift" suggests potential positive regulatory changes that could impact the broader physical therapy industry's reimbursement environment.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to increased net income, earnings per share, and a declared quarterly dividend of $0.45 per share.
• Employees: Potential positive impact from clinic expansion and growth, but also noted risks related to hiring, training, and retaining qualified employees, and potential impact of vaccination/testing mandates.
• Customers (Patients): Benefit from expanded access to physical therapy services through new clinics and home-care options.
• Creditors: Increased outstanding borrowings and interest expense indicate higher leverage, but strong operating income suggests ability to service debt.
• Partners (in joint ventures): Continued acquisition strategy involves retaining original practice owners with equity interests, indicating ongoing partnership opportunities.

Next Steps

• Filing of Quarterly Report on Form 10-Q with the SEC on November 7, 2025.
• Quarterly dividend of $0.45 per share payable on December 12, 2025, to shareholders of record on November 17, 2025.
• Continue implementation of a new financial and human resources system through the end of 2026.
• Continue strategy of acquiring multi-clinic outpatient physical therapy practices and home-care physical and speech therapy practices.
• Continue developing outpatient physical therapy clinics as satellites in existing partnerships.
• Continue acquiring companies that provide industrial injury prevention services.
• Progress on key initiatives expected to benefit 2026 growth and performance.
• Anticipated Medicare pricing lift.

Key Dates

Recommendation

The company delivered robust third-quarter results, significantly exceeding prior year performance in net income and Adjusted EBITDA, driven by successful strategic expansion and strong operational execution. The record-high patient visits per clinic and double-digit growth in both physical therapy and industrial injury prevention segments demonstrate healthy underlying business momentum. While there was a slight dip in operating results and some margin compression, the overall growth trajectory, reaffirmed full-year guidance, and an anticipated Medicare pricing lift for 2026 present a compelling investment case. The consistent dividend declaration further adds to shareholder value. These factors suggest a positive outlook and potential for continued share price appreciation.

Keywords

Physical Therapy, Industrial Injury Prevention, Healthcare Services, Clinic Expansion, Earnings Report, Adjusted EBITDA, Patient Visits, Dividends, Acquisitions, USPH